| Background: patients with angioplasty or stenting still experience high rates of restenosis events. Early animal and poorly controlled clinical studies of restenosis suggested that lowering serum lipid levels with 3-hydroxy-3-methylglutoryl coenzyme A reductase inhibitors maight prevent or delay the restenosis process. To investigate the role of lipids in the restenosis process, a number of clinical randomized control trials have started. This meta-analysis was performed to evaluate whether statin medicines can reduce the risk of coronary artery restenosis.Methods: We searched PubMed, EMBASE and the Cochrane Database for all published studies that evaluated the effect of statin therapy on restenosis. Random-effects models were applied to calculate pooled outcome data.Results: Seven published studies including 12973 patients with PCI were identified for inclusion in the analysis. There was a significant difference in the diameter of restenosis between statins group and placebo group. Statistical significance was defined at p value less than 0.05. Compared with placebo, statins has an influence on minimal luminal diameter and coronary artery restenosis MD=0.06,95%CI [0.05,0.08]; MD=0.85,95%CI?[0.76,0.95].Conclusion: Statins therapy has associated with a significantly lower risk of coronary artery restenosis. |
PDF Full Text Request